Bifidobacterium breve and Lactobacillus rhamnosus treatment is as effective as budesonide at reducing inflammation in a murine model for chronic asthma
about
Effects of orally administered galacto-oligosaccharides on immunological parameters in foals: a pilot study.Mast Cells in Lung Homeostasis: Beyond Type I HypersensitivityThe respiratory microbiome and innate immunity in asthmaHelsinki alert of biodiversity and health.Anti-Inflammatory Effects of Lactobacillus Rahmnosus and Bifidobacterium Breve on Cigarette Smoke Activated Human Macrophages.Perioperative supplementation with bifidobacteria improves postoperative nutritional recovery, inflammatory response, and fecal microbiota in patients undergoing colorectal surgery: a prospective, randomized clinical trial.The Airway Microbiome at Birth.Effects of Pseudomonas aeruginosa and Streptococcus mitis mixed infection on TLR4-mediated immune response in acute pneumonia mouse model.Microbiome, probiotics and neurodegenerative diseases: deciphering the gut brain axis.The development of allergic inflammation in a murine house dust mite asthma model is suppressed by synbiotic mixtures of non-digestible oligosaccharides and Bifidobacterium breve M-16V.Dietary galacto-oligosaccharides prevent airway eosinophilia and hyperresponsiveness in a murine house dust mite-induced asthma model.Measurement of airway function using invasive and non-invasive methods in mild and severe models for allergic airway inflammation in mice.Oral administration of Clostridium butyricum CGMCC0313-1 reduces ovalbumin-induced allergic airway inflammation in mice.Diet, Microbiota and Gut-Lung ConnectionHuman Microbe-Disease Association Prediction Based on Adaptive BoostingThe Combination Therapy of Dietary Galacto-Oligosaccharides With Budesonide Reduces Pulmonary Th2 Driving Mediators and Mast Cell Degranulation in a Murine Model of House Dust Mite Induced AsthmaBifidobacterium breve MRx0004 protects against airway inflammation in a severe asthma model by suppressing both neutrophil and eosinophil lung infiltration
P2860
Q34560290-454BF4C8-667F-41C9-87F3-5B94BBDB0D52Q34628122-A47EBEE5-D822-4B8A-BD8F-FB80BF0A2B25Q35430866-F5E75A67-3AF6-4BFF-9A0E-6859C1ECE5EBQ35612185-CBBCBFE9-2D45-44FF-AF32-08AFF3F1069AQ35758923-9D04C139-18AE-4379-900C-E6B822683976Q36875919-8E8D67BE-4B14-4233-A03E-00FB31E7EA8DQ37151241-2E8070A4-0C27-4E7E-AA6A-4CC1EB4CA4A5Q37738043-81393767-E2A2-4A05-B237-43CC109EFBBDQ39393210-EDBD56AE-1D1B-410D-A7F0-99F638718AEAQ39846853-09D8552B-F73D-4689-B54C-19A7BFAE259CQ41810665-09E31735-B0FF-433B-93DC-9C66E6C60834Q42784339-BCF81CAE-34F0-44BE-AE66-ED6A63AAE04FQ47989952-269EECF2-FE0D-44A5-9B24-55CA8150E13EQ57072837-F94815B7-91EA-40ED-999C-D1D7A3DBC8ECQ57816760-7FC2104D-1A1C-4E63-80CE-DA706427D22AQ58572662-7D29BED8-3D20-41C9-A63E-A1D103EFF559Q58786962-539C8D8A-0B87-426D-9144-B0B1422DA044
P2860
Bifidobacterium breve and Lactobacillus rhamnosus treatment is as effective as budesonide at reducing inflammation in a murine model for chronic asthma
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Bifidobacterium breve and Lact ...... urine model for chronic asthma
@en
Bifidobacterium breve and Lact ...... rine model for chronic asthma.
@nl
type
label
Bifidobacterium breve and Lact ...... urine model for chronic asthma
@en
Bifidobacterium breve and Lact ...... rine model for chronic asthma.
@nl
prefLabel
Bifidobacterium breve and Lact ...... urine model for chronic asthma
@en
Bifidobacterium breve and Lact ...... rine model for chronic asthma.
@nl
P2093
P2860
P356
P1433
P1476
Bifidobacterium breve and Lact ...... urine model for chronic asthma
@en
P2093
Aletta D Kraneveld
Arjan P Vos
Gert Folkerts
Jeroen van Bergenhenegouwen
Johan Garssen
Louis Boon
Mary E Morgan
Niki A Georgiou
Seil Sagar
P2860
P2888
P356
10.1186/1465-9921-15-46
P577
2014-04-16T00:00:00Z
P5875
P6179
1048072816